Study population
AGS
CHILBLAIN LUPUS
Patients demonstrating ≥ 2 signs and symptoms and with a confirmed genetic diagnosis of NNS/CANDLE, SAVI, or AGS (including familial chilblain lupus) were eligible. Patients with NNS/CANDLE or SAVI ≥ 17.5 months of age and patients with AGS ≥ 6 months of age were included in the trial [ ≥ 0.5 for patients with NNS/CANDLE at Visit 2, ≥ 1.0 for patients with SAVI at Visit 6, and ≥ 0.5 for patients with AGS at Visit 6